IV Acyclovir Dosing for Disseminated Shingles
For possible disseminated varicella-zoster infection (shingles), administer intravenous acyclovir at 10 mg/kg every 8 hours, with consideration of 15 mg/kg every 8 hours in patients with normal renal function, given for 7-14 days depending on clinical severity and immune status.
Dosing Regimen
The FDA-approved dose for disseminated VZV infection in immunocompromised patients is 500 mg/m² every 8 hours for 7 days 1. This translates to approximately 10 mg/kg every 8 hours in most adults 2.
Dose Optimization Considerations
- Standard dose: 10 mg/kg IV every 8 hours is the most commonly used and safest regimen 2, 3
- Higher dose: 15 mg/kg IV every 8 hours may be considered because VZV is less sensitive to acyclovir than HSV, but this requires normal renal function and frequent monitoring 2
- Duration: 7 days for most immunocompromised patients 1, 4; extend to 10-14 days for CNS involvement or severe dissemination 2
- Prolonged therapy: Immunocompromised patients may require extended courses beyond 7 days 2
Critical Safety Requirements
Mandatory Precautions
Adequate hydration is essential to prevent acyclovir crystal precipitation in renal tubules, which can cause acute renal failure 1. The maximum solubility of free acyclovir is 2.5 mg/mL at 37°C 1.
- Administer as slow IV infusion over 1 hour (never bolus) 4
- Ensure adequate urine output before and during administration
- Monitor renal function frequently, especially at higher doses 2, 1
Dose Adjustment for Renal Impairment
Acyclovir elimination is 62-91% renal, making dose adjustment critical 1:
- CrCl >80 mL/min: Standard dosing
- CrCl 50-80 mL/min: Reduce frequency or dose
- CrCl 15-50 mL/min: Significant reduction required
- Anuric patients: Half-life increases from 2.5 to 19.5 hours 1
Neurologic Monitoring
Approximately 1% of patients develop encephalopathic changes (lethargy, confusion, tremors, hallucinations, seizures, or coma) 1. Monitor mental status, particularly in patients with:
- Underlying neurologic abnormalities
- Renal impairment
- Hepatic dysfunction
- Electrolyte abnormalities
- Significant hypoxia 1
Clinical Context
The evidence strongly supports IV acyclovir for disseminated VZV. In the pivotal FDA trial, IV acyclovir at 500 mg/m² every 8 hours significantly reduced cutaneous and visceral dissemination in immunocompromised patients with zoster 1, 4. The drug halted progression, decreased new lesion formation, reduced acute pain, and lessened visceral complications 3, 4.
Why 10 mg/kg is Standard Despite VZV's Lower Sensitivity
While VZV is less sensitive to acyclovir than HSV 2, 3, most clinicians use 10 mg/kg every 8 hours rather than 15 mg/kg because:
- The higher dose causes nausea, vomiting, and transiently elevated creatinine in a substantial number of patients 5
- The 10 mg/kg dose has proven efficacy in clinical trials 1, 4
- Renal toxicity risk increases with higher doses 2, 1, 5
Use 15 mg/kg only if: renal function is normal, patient is closely monitored, and clinical severity warrants aggressive therapy 2.
Special Populations
- Geriatric patients: Higher plasma concentrations due to age-related renal decline; dose reduction often required 1
- Pediatric patients: Same weight-based dosing (10 mg/kg every 8 hours) 1
- Pregnancy: Use only if potential benefit justifies risk; not teratogenic in animal studies 1
Common Pitfalls to Avoid
- Bolus administration: Always infuse over 1 hour to prevent renal crystallization 1, 4
- Inadequate hydration: Ensure robust fluid intake before and during therapy 1, 3
- Ignoring renal function: Failure to adjust for impaired creatinine clearance leads to toxicity 1
- Premature discontinuation: Complete the full 7-day course minimum; extend for severe or CNS disease 2, 4
- Missing drug interactions: Probenecid increases acyclovir levels and half-life 1